Radcliffe & CardioNerds @AHA22: IRONMAN: Intravenous Ferric Derisomaltose in HF With Reduced EF

Published: 23 Nov 2022

  • Views:

    Views Icon 276
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

AHA 22 - Dr Rawan Amir, CardioNerds Fellow (Johns Hopkins Hospital, US) joins us in this collaboration between the @CardioNerds and Radcliffe Cardiology to interview Dr Paul Kalra (Portsmouth Hosp Univ NHS Trust, UK), investigator of the late-breaking IRONMAN trial (NCT02642562).

This randomised, open-label multicentre trial assessed the effectiveness of intravenous iron treatment compared to standard care in patients with heart failure and iron deficiency.

The trail demonstrated that in a broad range of patients with heart failure, a reduced LVEF and iron deficiency, administration of IV FDI was associated with a lower risk of recurrent heart failure hospitalizations and CV death, which approached statistical significance.

Access our full AHA 22 Scientific Coverage here.  

Recorded remotely from Portsmouth and Baltimore, 2022. 

Editor: Mirjam Boros

Video Specialist: Oliver Miles